Srihari Gopal

18.2k total citations
91 papers, 2.9k citations indexed

About

Srihari Gopal is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Neurology. According to data from OpenAlex, Srihari Gopal has authored 91 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Psychiatry and Mental health, 24 papers in Pediatrics, Perinatology and Child Health and 21 papers in Neurology. Recurrent topics in Srihari Gopal's work include Schizophrenia research and treatment (82 papers), Pharmaceutical studies and practices (23 papers) and Botulinum Toxin and Related Neurological Disorders (19 papers). Srihari Gopal is often cited by papers focused on Schizophrenia research and treatment (82 papers), Pharmaceutical studies and practices (23 papers) and Botulinum Toxin and Related Neurological Disorders (19 papers). Srihari Gopal collaborates with scholars based in United States, Belgium and Germany. Srihari Gopal's co-authors include David Hough, Isaac Nuamah, Pilar Lim, Mariëlle Eerdekens, Cristiana Gassmann-Mayer, Bart Remmerie, Adam Savitz, Haiyan Xu, Ujjwala Vijapurkar and Morozova Ma and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Scientific Reports.

In The Last Decade

Srihari Gopal

90 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Srihari Gopal United States 29 2.4k 595 534 480 390 91 2.9k
Mark Taylor United Kingdom 24 2.0k 0.8× 481 0.8× 956 1.8× 291 0.6× 137 0.4× 73 2.9k
Christian R. Dolder United States 23 2.5k 1.0× 485 0.8× 852 1.6× 193 0.4× 153 0.4× 44 3.4k
Bart Remmerie United States 22 1.2k 0.5× 219 0.4× 201 0.4× 330 0.7× 158 0.4× 46 1.7k
G. William MacEwan Canada 22 1.4k 0.6× 314 0.5× 501 0.9× 138 0.3× 138 0.4× 82 2.7k
Susan G. Leckband United States 13 1.4k 0.6× 286 0.5× 503 0.9× 250 0.5× 201 0.5× 24 2.2k
A. Schreiner Germany 23 1.4k 0.6× 317 0.5× 437 0.8× 325 0.7× 221 0.6× 116 1.9k
Jonathan M. Meyer United States 28 2.6k 1.1× 299 0.5× 366 0.7× 191 0.4× 213 0.5× 95 3.7k
Mirza W. Ali United States 16 2.0k 0.8× 292 0.5× 283 0.5× 252 0.5× 277 0.7× 30 2.6k
Karen P. Hayhurst United Kingdom 15 1.3k 0.5× 382 0.6× 335 0.6× 120 0.3× 100 0.3× 38 1.7k
Nancy Chen United States 20 1.0k 0.4× 238 0.4× 243 0.5× 200 0.4× 88 0.2× 61 2.0k

Countries citing papers authored by Srihari Gopal

Since Specialization
Citations

This map shows the geographic impact of Srihari Gopal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srihari Gopal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srihari Gopal more than expected).

Fields of papers citing papers by Srihari Gopal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srihari Gopal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srihari Gopal. The network helps show where Srihari Gopal may publish in the future.

Co-authorship network of co-authors of Srihari Gopal

This figure shows the co-authorship network connecting the top 25 collaborators of Srihari Gopal. A scholar is included among the top collaborators of Srihari Gopal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srihari Gopal. Srihari Gopal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
T’jollyn, Huybrecht, Alberto Russu, Raja Venkatasubramanian, et al.. (2024). Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I). European Journal of Drug Metabolism and Pharmacokinetics. 49(4). 477–489. 1 indexed citations
2.
Benson, Carmela, Dean Najarian, Steven Wang, et al.. (2023). The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment. Volume 19. 531–545. 20 indexed citations
3.
Turkoz, Ibrahim, Mehmet Daskiran, H. Lynn Starr, et al.. (2022). Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections. Neuropsychiatric Disease and Treatment. Volume 18. 1927–1937. 2 indexed citations
4.
Li, Gang, Alexander Keenan, Mehmet Daskiran, et al.. (2021). Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. Patient Preference and Adherence. Volume 15. 2239–2248. 17 indexed citations
5.
6.
Gopal, Srihari, et al.. (2020). <p>Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study</p>. Neuropsychiatric Disease and Treatment. Volume 16. 681–690. 3 indexed citations
7.
Sanga, Panna, Isaac Nuamah, Alexander Keenan, et al.. (2020). <p>Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire</p>. Patient Preference and Adherence. Volume 14. 1093–1102. 46 indexed citations
8.
Mathews, Maju, Srihari Gopal, Isaac Nuamah, et al.. (2019). <p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p>. Neuropsychiatric Disease and Treatment. Volume 15. 1365–1379. 31 indexed citations
9.
Sliwa, Jennifer Kern, Adam Savitz, Isaac Nuamah, et al.. (2018). An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. Perspectives In Psychiatric Care. 54(4). 530–538. 11 indexed citations
10.
Mathews, Maju, Huiling Pei, Adam Savitz, et al.. (2018). Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. Clinical Drug Investigation. 38(8). 695–702. 5 indexed citations
11.
12.
Katz, Eva G., Brett Hauber, Srihari Gopal, et al.. (2016). Physician and patient benefit&ndash;risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Preference and Adherence. Volume 10. 2127–2139. 21 indexed citations
13.
Li, Qingqin S., Nathan E. Wineinger, Dong‐Jing Fu, et al.. (2016). Genome-wide association study of paliperidone efficacy. Pharmacogenetics and Genomics. 27(1). 7–18. 36 indexed citations
14.
Savitz, Adam, Haiyan Xu, Srihari Gopal, et al.. (2016). Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. The International Journal of Neuropsychopharmacology. 19(7). pyw018–pyw018. 128 indexed citations
15.
Savitz, Adam, Rosanne Lane, Isaac Nuamah, et al.. (2015). Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study. Journal of Child and Adolescent Psychopharmacology. 25(7). 548–557. 13 indexed citations
16.
Markowitz, Michael A., Dong‐Jing Fu, Bennett Levitan, et al.. (2013). Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Annals of General Psychiatry. 12(1). 22–22. 28 indexed citations
17.
18.
Nasrallah, Henry A., Srihari Gopal, Cristiana Gassmann-Mayer, et al.. (2010). A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia. Neuropsychopharmacology. 35(10). 2072–2082. 126 indexed citations
19.
Gopal, Srihari, David Hough, Haiyan Xu, et al.. (2010). Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. International Clinical Psychopharmacology. 25(5). 247–256. 133 indexed citations
20.
Gopal, Srihari, David C. Steffens, Michelle Kramer, & Catherine M. Olsen. (2005). Symptomatic Remission in Patients With Bipolar Mania. The Journal of Clinical Psychiatry. 66(8). 1016–1020. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Taylor Breakdown of academic impact, for papers by Christian R. Dolder Breakdown of academic impact, for papers by Bart Remmerie Breakdown of academic impact, for papers by G. William MacEwan Breakdown of academic impact, for papers by Susan G. Leckband Breakdown of academic impact, for papers by A. Schreiner Breakdown of academic impact, for papers by Jonathan M. Meyer Breakdown of academic impact, for papers by Mirza W. Ali Breakdown of academic impact, for papers by Karen P. Hayhurst Breakdown of academic impact, for papers by Nancy Chen
Rankless by CCL
2026